Updates are available Correction dated 2025-02-25
Click to view Correction: https://doi.org/10.1038/s41586-025-08826-1
-
Authors
Tadross, John A. https://orcid.org/0000-0002-8424-1252
Steuernagel, Lukas https://orcid.org/0000-0003-0043-1436
Dowsett, Georgina K. C.
Kentistou, Katherine A. https://orcid.org/0000-0002-5816-664X
Lundh, Sofia https://orcid.org/0000-0002-4552-0312
Porniece, Marta https://orcid.org/0000-0003-2330-5846
Klemm, Paul https://orcid.org/0000-0002-5985-1737
Rainbow, Kara
Hvid, Henning
Kania, Katarzyna
Polex-Wolf, Joseph https://orcid.org/0000-0002-0441-8872
Knudsen, Lotte Bjerre https://orcid.org/0000-0002-2439-7116
Pyke, Charles
Perry, John R. B. https://orcid.org/0000-0001-6483-3771
Lam, Brian Y. H. https://orcid.org/0000-0002-3638-9025
Brüning, Jens C. https://orcid.org/0000-0002-6619-0092
Yeo, Giles S. H. https://orcid.org/0000-0001-8823-3615
- License Information
-
More Information
Article History
Received: 20 September 2023
Accepted: 9 December 2024
First Online: 5 February 2025
Change Date: 25 February 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-025-08826-1
Competing interests
: S.L., J.P.-W., L.B.K. and C.P. are Novo Nordisk employees and/or shareholders. J.R.B.P. is an employee and shareholder of Insmed. J.R.B.P. also receives research funding from GSK and consultancy fees from WW International. B.Y.H.L. provides remunerated consultancy for Nuntius Therapeutics. G.S.H.Y. receives grant funding from Novo Nordisk and consults for both Novo Nordisk and Eli Lilly and Company. J.C.B. is co-founder of Cerapeutix and has received research funding through collaborations with Sanofi Aventis and Novo Nordisk Inc., he also consulted for Eli Lilly and Company and Novo Nordisk, all of which did not affect the content of this article. The other authors declare no competing interests.
